Abstracts from the Emerging Science Series, June 19, 2013
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
CPT1A Methylation is a Novel Epigenetic Marker of Cardiovascular Risk
Stella Aslibekyan, Marguerite M. Irvin, Jin Sha, Degui Zhi, Univ of Alabama at Birmingham, Birmingham, AL; Krista Stanton Thibeault, Hudson Alpha Inst for Biotechnology, Huntsville, AL; Michael Y. Tsai, Univ of Minnesota, Minneapolis, MN; Paul Hopkins, Univ of Utah, Salt Lake City, UT; Ingrid B. Borecki, Washington Univ at St Louis, St Louis, MO; Jose M. Ordovas, Tufts Univ, Boston, MA; Devin M. Absher, Hudson Alpha Inst for Biotechnology, Huntsville, AL; Donna K. Arnett, Univ of Alabama at Birmingham, Birmingham, AL
Introduction: Inter-individual variability in plasma lipid levels and other cardiovascular risk phenotypes is influenced by both genetic and environmental factors. However, known predictors explain only a limited portion of the observed variability. We hypothesized that epigenetic changes such as DNA methylation contribute to the architecture of complex metabolic traits such as plasma lipids and thus affect cardiovascular risk. Methods: We isolated DNA from CD4+ T-cells and quantified methylation at 461,281 CpG sites using the Infinium HumanMethylation450 BeadChip Kit in 888 participants of the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study. Participants were randomly allocated to either discovery (n=593) or replication (n=295) data …